The Uncertain Value of Renal Artery Interventions Where Are We Now? by Textor, Stephen C. et al.
T
W
S
R
I
a
c
w
p
m
t
v
t
t
t
e
s
p
t
n
o
j
C
T
f
i
s
l
d
r
l
v
F
H
M
P
T
R
s
M
b
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 3 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 8 . 1 2 . 0 0 8he Uncertain Value of Renal Artery Interventions
here Are We Now?
tephen C. Textor, MD,* Lilach Lerman, MD, PHD,* Michael McKusick, MD†
ochester, Minnesota
mproved technology for detection of and endovascular procedures for renal artery stenosis due to
therosclerosis has been associated with increases in renal artery intervention. Hypertension with ac-
elerated target organ injury, reduced kidney function, and episodic circulatory congestion in patients
ith renovascular disease predict reduced patient survival. Recent studies indicate that activation of
ressor mechanisms depends upon hemodynamic gradients that are often overrated by visual esti-
ates. Although activation of the renin-angiotensin system initiates renovascular hypertension, addi-
ional mechanisms perpetuate vascular remodeling and kidney injury that may not depend upon large
essel occlusion. Major advances in medical therapy have led to initiation of at least 4 major prospec-
ive trials comparing optimal medical therapy with or without stenting. Up to now, outcome data fail
o support broad application of renal revascularization, including results from a recent large, prospec-
ive trial from the United Kingdom, despite small groups of patients that experience major clinical ben-
ﬁt. The ambiguity of these results partly reﬂect poor characterization of the severity of vascular le-
ions and competing risks within the population related to aging and pre-existing disease. Many
atients currently undergoing renal artery interventions derive little net beneﬁt and some are exposed
o signiﬁcant complications, including atheroembolic disease. Determining the appropriate role for re-
al artery interventions will depend on developing better methods for judging the role of large vessel
cclusive disease regarding tissue oxygenation, activation of proﬁbrotic pathways, and irreversible in-
ury in the post-stenotic kidney. (J Am Coll Cardiol Intv 2009;2:175–82) © 2009 by the American
ollege of Cardiology Foundationd
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sechnical advances in endovascular intervention
or renal artery atherosclerosis have been stunning
n recent years. Even complex atherosclerotic le-
ions are routinely treated with stents achieving
umen patency in more than 98% of cases. These
evelopments allow more patients with extensive
enovascular disease to be considered for revascu-
arization than ever before. Why, then, does endo-
ascular stenting for patients with renal artery
rom the *Department of Medicine, Division of Nephrology and
ypertension, and the †Department of Interventional Radiology,
ayo Clinic, Rochester, Minnesota. Supported by Award Number
01HL085307 from National Heart, Lung, and Blood Institute. Drs.
extor and McKusick are site principal investigators at Mayo Clinic,
ochester for the CORAL (Cardiovascular Outcomes of Renal Athero-
clerotic Lesions) trial.K
anuscript received July 18, 2008; revised manuscript received Decem-
er 5, 2008, accepted December 11, 2008.isease remain controversial? Debates appear reg-
larly at national meetings and in major journals,
eflecting both skepticism and large gaps in per-
uasive outcome data (1,2).
See page 183
These debates underscore a major divergence be-
ween individual physicians and subspecialty groups
uch as internists, cardiologists, and nephrologists
aring for patients with atherosclerotic renal artery
tenosis (RAS). Clinicians recognize that renovascu-
ar occlusive disease accelerates hypertension, is asso-
iated with high cardiovascular mortality, and can
ead to irreversible loss of kidney function (3). Up to
ow, however, prospective clinical trials—some
mall, and some recent larger trials from the United
ingdom and Europe—fail to demonstrate benefits
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176f renal revascularization regarding cardiovascular or kidney
utcomes as compared with intensive medical therapy alone
4,5). Occasionally, renal artery interventions lead to adverse
utcomes, including catastrophic complications such as athe-
oembolic disease or aortic dissection. These results have been
ufficiently ambiguous so that no fewer than 4 prospective,
andomized trials have been undertaken specifically to examine
hether stenting adds benefit as compared with optimized
edical therapy alone (6).
Despite these concerns, renal artery interventions seem to
ave irresistible appeal, particularly in the U.S. Reviews of
edicare claims indicate the number of procedures between
996 and 2005 rose more than 4-fold, from 8,000 to more
han 35,000 (6,7). The increased rates of intervention
ppear to be driven mainly by cardiologists, rather than
nterventional radiologists or surgeons. The Center for
edicaid and Medicare Services convened a meeting of its
edical advisory group in 2007 regarding treatment of
therosclerotic RAS. This meeting followed a formal review
y the Agency for Healthcare Research and Quality that
ndicated that the available published data were insufficient
o conclude substantial benefit regarding blood pressure
ontrol, kidney function, or mortality for atherosclerotic
enal artery disease (4). Although no change in coverage has
yet appeared, there remains a
concern that these procedures
are overused in the U.S. Reports
that the U.S. per capita health
care spending is nearly double
that of other Western countries,
otably Australia, Canada, Germany, the Netherlands,
ew Zealand, and the United Kingdom, are consistent with
his concern. Despite higher costs, outcomes regarding
preventable deaths before the age of 75” are actually higher
n the U.S. than in these countries (8).
Professional societies have offered “consensus” statements
reely supporting peripheral arterial interventions, including
enal artery stenting. Several of these offer the position that
enal artery stenting procedures are “reasonable” or “usually
ffective,” despite the lack of supporting evidence (9). Some
ndorse screening aortography to examine the renal arteries
s part of coronary angiography for patients considered at
isk for having renovascular disease (10). The nephrology
ommunity has viewed these developments with increasing
kepticism (11). This review will explore the current status
f renal artery interventions regarding complex hypertension
nd protecting kidney function. We hope to highlight areas
here further information is needed to provide intervention
or patients who would truly benefit.
opulation at Risk
ome of the rising prevalence of systemic atherosclerotic
bbreviations
nd Acronyms
AS  renal artery stenosisisease relates directly to the aging population. In some lespects, the problem of atherosclerotic renal artery disease is
n outgrowth of success from reduced mortality from coronary
rtery disease and from other causes. The average age reported
n interventional series rose from the mid-50s to the early 70s
ver the last 2 decades. Population-based studies indicate that
mong a free-living community, RAS above 60% (by ultra-
ound) can be detected in 6.8% of individuals above age 65
ears. Screening for renal artery disease in subjects with
oronary disease or atherosclerotic peripheral vascular disease
nd hypertension yields a prevalence of RAS between 18% and
0% (9). Hypertension and decreased glomerular filtration rate
stimated by the MDRD (Modification of Diet in Renal
isease) study equation also are nearly ubiquitous in this
opulation. Renewed emphasis on attaining optimal blood
ressure control and the association of reduced kidney function
ith adverse cardiovascular risk understandably predisposes
any clinicians to revascularize the kidney when the opportu-
ity arises.
Clinical manifestations of RAS reflect complications of
levated arterial pressure and impaired kidney function.
tudies of patients with presumed renovascular hyperten-
ion indicate that circadian pressure rhythms are frequently
isturbed leading to “nondipper” status with accelerated
arget organ manifestations. Patients with limited cardiac
eserve can develop worsening congestive heart failure
sometimes designated “flash” pulmonary edema) that can
e managed more easily after renal revascularization. In the
ast, these features were refractory to most medical therapy.
n recent years, however, the availability of effective, well-
olerated antihypertensive therapy including agents that
lock the renin-angiotensin-aldosterone system largely has
vercome these problems. Series of patients successfully
reated for “resistant hypertension” routinely include many
ith associated renovascular disease. Most of these patients
ow can be treated to “goal” levels with attention to drug
election and management of volume effects (12). The
ORAL (Cardiovascular Outcomes of Renal Atheroscle-
otic Lesions) study (13) requires external monitoring to
nsure that participants be treated to goal blood pressures
onsistent with Joint National Commission (JNC)-7 guide-
ines. Renin-angiotensin system blockade with candesartan
s provided for all patients in this trial.
echanisms of Hypertension
he potential for reduced renal perfusion pressure to induce
systemic rise in blood pressure remains a seminal obser-
ation in hypertension. Renovascular hypertension induced
y renal-artery clips, or more recently by progressive renal
rtery occlusion induced by a proinflammatory material such
s a copper stent (14), remains among the most widely
tudied models of hypertension.
Reduced perfusion pressure beyond a stenotic kidney
esion releases renin and thereby activates angiotensin II.
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177arly studies using angiotensin-converting enzyme inhibi-
ion, and more recent studies with genetic knockout animals
acking the angiotensin I receptor, confirm that renovascular
ypertension requires the angiotensin effect to develop. The
ustained pressor role for the renin-angiotensin system
epends greatly upon whether a normal “contralateral”
idney is present to excrete sodium (designated 2-kidney-
-clip hypertension) as we have reviewed elsewhere (3). The
agnitude of renovascular occlusion required to activate the
enin-angiotensin system in this disorder is underscored by
ecent studies in humans by De Bruyne et al. (15). These
nvestigators demonstrate that renin release beyond an
nflated occlusive balloon is proportional to the gradient
eveloped across the lesion and requires at least a 10%
radient. These effects are illustrated in Figure 1. Early
tudies using cast models of vascular occlusion suggest that
emodynamic effects of pressure or flow reduction are
etected only above 60% to 70% lumen occlusion (3) Some
linical trials employ a visually estimated threshold of “50%”
tenosis (16). Recent experience (14) demonstrates that such
stimates commonly overstate the degree of occlusion.
hese studies are hampered by the lack of standardized
ethods to assess the status of the intrarenal microcircula-
ion and renal hemodynamic and functional reserve (17).
he fact that many renal artery stenoses fail to produce
emodynamic gradients may partly account for the limited
enefit observed in previous trials of renal revascularization.
To complicate matters, activation of the renin-
ngiotensin system is often transient. Recent studies indi-
Figure 1. Trans-Stenotic Gradient Required for Renin Release
Balloon-induced, controlled, graded stenosis in human subjects followed by
measurement of the plasma renin concentration in the vein of the stenotic
kidney (solid circles), in the vein of the nonstenotic kidney (open circles),
and in the aorta (squares). These studies underscore the hemodynamic
requirements for activation of the renin-angiotensin system in subjects with
renal artery stenosis. Such effects require development of a pressure gradi-
ent across the lesion. Reproduced, with permission, from De Bruyne et al.d
(15). BL  baseline.ate that additional pressor systems become activated with
ime, including a production of reactive oxygen species
eading to “oxidative stress” (18). Sympathetic nerve activa-
ion and recruitment of endothelium-based pressor systems
re commonly identified, only some of which are reversible
pon restoring renal perfusion (19). Vascular responses
ithin the kidney are modified by early atherogenic changes
elated to high cholesterol levels (20). Inflammatory and
rofibrogenic pathways become activated during sustained
enal artery occlusion and perpetuate irreversible renal
amage. These factors lead to scarring and loss of glomer-
lar filtration with time. At some point, restoring renal
rtery perfusion no longer produces meaningful recovery of
unction.
It is important to recognize that the principles and
uccess of vascular intervention in the coronary and periph-
ral arteries may not extend to renal circulation. Unlike
lood vessels supplying the heart or brain, the vessels to the
idney deliver an excess of oxygenated blood, far more than
eeded for basal metabolic demands (21). Much of the
xygen consumption beyond basal levels is related to solute
ransport, which can vary widely and can increase efficiency
nder stress. Moreover, functional units of the kidney can
hibernate” and can regenerate after an ischemic insult.
ence, the kidney can be less susceptible to moderate
hanges in blood flow than either heart or neural tissue in
he absence of pre-existing renal disease. Deterioration of
enal function beyond a stenotic lesion then may reflect late
ffects of sustained hemodynamic injury or result from other
brogenic processes that do not primarily reflect hemody-
amic changes (22).
echnical Issues Related to Renal Artery Stenting
ools used for percutaneous renal artery intervention have
mproved over recent years with pre-mounted, ultra-low-
rofile stent/balloon combinations on 0.014- or 0.018-inch
ire platforms designed specifically for renal artery use.
one are the days of manually shaping stents over 5- or 7-F
alloon catheters designed for 0.035-inch guidewires. The
se of steerable guiding catheters is now routine and allows
or gentle engagement of renal artery ostia. More precise
maging tools allow stent placement to ensure lesion cover-
ge and targeted stent extension into the abdominal aorta.
hese tools undoubtedly allow management of more com-
lex cases safely without adding much procedural risk.
Atheroembolic disease remains a major concern with
anipulation of the abdominal aorta. Renal artery manip-
lation is a predictor of serious embolic events (23), and
mall embolic showers are often undetected. Distal embolic
rotection devices designed originally for coronary and
erebrovascular applications have been employed in the
enal arteries in an effort to mitigate renal injury. These
evices include either filter wires or balloon occlusion and
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178spiration designs. Embolic protection appears logical and
as been used successfully in several series (24,25).
However, the true benefits of embolic protection devices
or the renal circulation remain unproven in general use.
ooper et al. (26) published a randomized, prospective trial
hat showed a decline in estimated glomerular filtration rate
n patients treated with no protective device, in patients
reated with a distal embolic protection device (Angiogard,
ordis Endovascular, Miami Lakes, Florida), and in pa-
ients treated with a platelet glycoprotein IIb/IIIa inhibitor
abciximab) as an antithrombotic agent. The only group
ith no loss of glomerular filtration rate was treated with
oth the embolic protection device and abciximab. A
reatment interaction was observed between the use of the
ngiogard and abciximab in this trial. This raises the
uestion of whether use of the device pre-disposed the
atient to have intravascular thrombosis. Regardless of the
eason, the company producing the Angiogard has ceased its
evelopment, and its use has been discontinued in the
ORAL trial. Other devices are sometimes employed and
equire considerable operator experience for optimal use.
arly bifurcation of the renal artery with insufficient length
or the device deployment sometimes presents anatomic
imitations and may render up to 50% of the renal paren-
hyma vulnerable to embolization even with a device in
lace. As a practical matter, development of renal embolic
vents can occur over days and weeks after vessel manipu-
ation, making temporary protection have only limited
Figure 2. Clinical Events in Patients With RAS
New clinical events reﬂected as Medicare claims in the 2 years after identi-
ﬁcation of new atherosclerotic renal artery stenosis (RAS), based on a
review of 1,085,250 claims between 1997 and 2001. These observations
conﬁrm the increased rate of new cardiovascular events, including death, in
patients with identiﬁed renovascular disease in the population above age
65 years in the U.S. Cardiovascular events were far more frequent than fur-
ther loss of kidney function (CKD). Data taken, with permission, from Kalra
et al. (27). ASPVD  atherosclerotic peripheral vascular disease; CAD  cor-
onary artery disease; CHF  congestive heart failure; CVA  cerebrovascu-
lar accident; Dx  diagnosis; TIA  transient ischemic attack.alue.ompeting Risk and Results of
evascularization for RAS
major confounder related to treatment of renal artery
therosclerotic disease is “competing risk” from other man-
festations of atherosclerosis. Nearly all of these patients
ave pre-existing hypertension and/or other risk factors,
uch as smoking, advanced age, dyslipidemia, diabetes. A
eview of Medicare claims data for newly identified subjects
ith claims attributable to renal artery disease indicates that
laims over the following 2 years vastly exceed those of a
ontrol population without renal artery disease. These
laims mainly relate to new cardiovascular disease including
cute coronary syndromes, congestive heart failure, stroke,
nd similar conditions (Fig. 2) (27). The risks of these
vents were numerically far greater than complications
elated to renal failure. Some argue that renal artery disease
rimarily reflects the burden of atherosclerotic disease else-
here, but does not itself determine the outcome of this
isease, at least over the near term. This conclusion is
onsistent with follow-up data over periods up to 8 years
omparing surgical renal revascularization with intensive
edical therapy for renal artery atherosclerotic lesions in a
andomized, prospective trial (28) (Fig. 3). Several small
rials of percutaneous angioplasty nearly a decade ago failed
o identify clinical benefits in terms of blood pressure
Figure 3. Survival After Medical Therapy or Renal Artery
Revascularization
Follow-up data regarding survival after intensive medical therapy as com-
pared with surgical revascularization of patients with atherosclerotic reno-
vascular disease affecting the entire renal mass. Despite excellent vascular
patency, no survival differences for the groups were apparent during fol-
low-up for more than 7 years. The cumulative mortality exceeded 50% over
5 years, which is consistent with widespread atherosclerotic vascular dis-
ease that was not affected by renal artery reconstruction. Initial results
from the ASTRAL (Angioplasty and Stenting for Renal Artery Lesions) trial
including 806 patients are similar, identifying no detectable difference in
either progressive renal dysfunction or mortality (see text). Data taken, with
permission, from Uzzo et al. (28). Tx  treatment.
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179ontrol, renal function, or mortality during the short term,
s we have reviewed elsewhere (3). Many patients with
evere disease were not included in these trials, and analysis
as complicated by high rates of treatment crossover be-
ween medical and revascularization therapy.
Taken together, current data related to renal artery
nterventions do not support a major benefit for most
atients with atherosclerotic disease. Table 1 summarizes
ome of the reasons for continued uncertainty regarding the
enefits of renal revascularization.
arge Trials in Progress
lockade of the renin-angiotensin system, statins, and
ntiplatelet therapy are now bedrocks for the clinical man-
gement of atherosclerotic disease, including RAS (29).
lthough the benefits of restoring blood flow to the kidney
ay appear to be obvious, vascular stenting carries well-
Table 1. Reasons for Uncertainty Regarding Renal Artery
Revascularization
1. Imprecise deﬁnition of “severity” regarding occlusive disease
Inclusion of subcritical lesions in clinical trials
Failure to deﬁne causal role in disease syndromes:
a. Hypertension
b. Declining kidney function
c. Congestive heart failure (circulatory congestion)
2. Failure to revascularize kidneys with potential for recovery
3. Lack of standard methods to assess renal hemodynamic/functional reserve
4. Compensatory actions of the nonstenotic kidney
5. Complications of the procedure, for example,
a. Atheroembolic disease
b. Vessel dissection/occlusion
c. Contrast nephrotoxicity
d. Ischemia/reperfusion injury
6. Advances in medical therapy for hypertension and atherosclerosis
a. Blockade of the renin-angiotensin system
b. Effective, well-tolerated antihypertensive drugs
c. Statins and other lipid-lowering drugs
d. Antiplatelet agents: aspirin, clopidogrel
e. Smoking cessation
7. Competing risks of comorbid disease
a. Aging population
b. Pre-existing coronary and cerebrovascular disease
c. Renovascular disease as an incidental ﬁnding
8. Negative outcomes data from randomized trials
a. PTRA trials
b. Surgical revascularization
c. ASTRAL (preliminary)
d. STAR (preliminary)
ASTRAL Angioplasty and Stenting for Renal Artery Lesions trial; PTRA percutaneous translu-
minal renal angioplasty; STAR  STent placement and BP and lipid lowering for progression of
renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery.ecognized risks of atheroembolic disease, restenosis, and iocal complications (e.g., vessel dissection and thrombosis)
hat remain problematic. Hence, whether endovascular
tenting provides additional benefits beyond meticulous
anagement of blood pressure, blockade of neurohumoral
ctivation, and management other risk factors is controver-
ial. This is the basic question underlying current prospec-
ive treatment trials such as the CORAL trial in the U.S.
nd the ASTRAL (Angioplasty and Stenting for Renal
rtery Lesions) trial in the United Kingdom.
Enrollment in the ASTRAL trial used somewhat ambig-
ous criteria to recruit patients “in whom clinicians were
ubstantially uncertain whether to recommend revascular-
zation” (5). Lesion severity exceeded 70% lumen occlusion
y most criteria. The mean serum creatinine in this trial was
.02 mg/dl. More than 90% of patients in both treatment
rms were treated with statins and aspirin. Angiotensin-
onverting enzyme inhibitors or angiotensin receptor block-
rs were used in 38% to 47% of patients. Initial results from
06 subjects in the ASTRAL trial with a median follow-up
f more than 2 years demonstrated no important differences
etween stenting and medical therapy (5). No differences
ere observed in mortality (7.4% vs. 8.2%) hospitalization
or congestive heart failure, serum creatinine changes, sys-
olic blood pressure, or time to first renal event in this trial.
omplete reports regarding the patient population and
utcome data have not yet been published.
The CORAL trial seeks to examine long-term outcome
ifferences (5 years) using observed cardiovascular events,
ather than blood pressure levels or renal function alone, in
ore than 1,000 patients. More than 600 subjects have been
lready enrolled. Enrollment and randomization criteria
equire more stringent definition of lesions exceeding 60%
umen occlusion and there are few exclusions, beyond
dvanced renal failure (creatinine above 4.0 mg/dl) and
educed left ventricular ejection fraction (below 30%). The
act that the National Institutes of Health is funding this
tudy reinforces the level of “equipoise” that remains be-
ween the risks and benefits of renal artery interventions.
cceptable candidates may have high-grade stenosis to a
olitary functioning kidney and/or episodes of congestive
eart failure. The investigators argue essentially that no
redible data establish a positive net benefit of renal revas-
ularization for any condition (1). Remarkably, initial results
onfirm that excellent risk factor improvement can be
chieved for the entire group of patients (30). Oversight
ommittees review blood pressure and lipid and glucose
evels for CORAL participants to ensure achievement of
goal” levels in both treatment arms. All subjects are treated
ith angiotensin receptor blockers and intensive manage-
ent of atherosclerotic disease using statins, smoking ces-
ation, and glucose control. There have been few crossovers
n the first 600 subjects enrolled.
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180here Do We Go From Here?
s a result of the negative results noted, nephrologists have
oved toward a more conservative clinical stance in recent
ears, perhaps as a pragmatic counterweight to enthusiastic
nterventional cardiologists and radiologists (11). Despite
he difficulty in demonstrating benefits in large groups,
ome patients do experience major improvements in kidney
unction and cardiovascular stability after successful renal
evascularization.
The challenge facing thoughtful clinicians in this arena is
o prevent conservatism from interfering with the best
nterests of patients who might benefit from renal artery
evascularization to a major degree. A recognized drawback
f clinical treatment trials is the intermixture of high-risk
nd low-risk subjects into the “average” of the entire cohort
31). Those actively managing patients with atherosclerotic
isease recognize that some individuals should be treated
ith revascularization.
Many criteria have been proposed to better define pa-
ients likely to benefit from renal artery intervention, in-
luding measurement of renal vein renin levels, circulating
rain natriuretic peptide, changes in renographic appearance
fter angiotensin-converting enzyme inhibition, and others.
n some instances, these maneuvers can be helpful, but most
ave proven to have low positive predictive value when
pplied to general populations. The most consistent predic-
or of benefit regarding both blood pressure response and
ecovery of kidney function has been the rate of change up
o the point of diagnosis and revascularization (32). Those
ndividuals detected soon after a major change in clinical
tatus are most likely to respond to revascularization. Figure
is an angiogram obtained from a patient in whom recently
dvancing renal insufficiency associated with bilateral renal
Figure 4. Stent Placement for High-Grade Bilateral RAS
Aortogram (left) demonstrating high-grade bilateral RAS near the origins. The
bilateral endovascular stent placement. This individual recently had developed
stent placement, serum creatinine fell to 1.6 mg/dl. A recent change in kidney
in Figure 2.rterial stenosis could be reversed after renal artery revascu-
arization. This example highlights the clinical observation
hat restoring renal perfusion to ischemic kidneys some-
imes does prevent progressive renal failure.
How does one identify such patients? Atherosclerotic
AS has a poorly defined relationship between the presence
f large vessel occlusive disease and target injury in the
idney. Unlike fibromuscular disease, the degree of severity
f vascular occlusion in atherosclerosis bears little relation-
hip to measured blood flow, kidney volume, degree of
brosis, or glomerular filtration rate (3). These observations
rovide the basis for experimental studies of interactions
etween vascular occlusion and other vectors of kidney
njury, including endothelial dysfunction, tissue oxidative
tress (18), and the atherosclerotic milieu produced by
yslipidemia (20). It is not clear whether high-grade vascu-
ar occlusion induces repeated episodes of transient kidney
schemia that activate profibrotic pathways similar to other
cute models. How to identify regional ischemia in human
idneys is not yet certain. Recent studies using blood oxygen
evel–dependent magnetic resonance indicate that post-
tenotic kidneys have a range of metabolic activity and
xygen consumption linked to active solute transport (33).
ur initial studies suggest that total vascular occlusion and
oss of filtration is associated with reduced levels of deoxy-
emoglobin and minimal change during furosemide admin-
stration (34). By contrast, viable, functioning kidneys
eyond an atherosclerotic lesion have relatively high levels
f accumulated deoxyhemoglobin, particularly in the me-
ulla. Such kidneys can respond briskly to reduce deoxyhe-
oglobin levels after intravenous administration of furo-
emide to reduce solute transport. Whether elevations of
eoxyhemoglobin and furosemide-suppressible oxygen con-
panel illustrates improved ﬂow to both kidneys on the aortogram after
in serum creatinine from 1.7 to 3.8 mg/dl over the previous 6 months. After
ion remains the best predictor of clinical recovery (see text). Abbreviation asright
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181umption induce cytokine release or toxic oxidative stress
arrants further study.
It is almost certain that many, if not most, patients now
eing subjected to endovascular stenting of the renal arteries
how only limited benefits, either regarding blood pressure
esponse or improvement in kidney function (11). Equally
mportant to recognize is that a subset of patients with
critical” RAS stands to have a major clinical benefit from
estoring kidney perfusion and major adverse outcomes if
ot detected and treated (6). Table 2 summarizes several
linical issues that address whether patients are likely to
arrant renal revascularization. Most imaging procedures
ocus specifically upon the anatomic severity and approach-
bility of renal vascular lesions. Although these character-
stics are important, they are clearly not sufficient to predict
he outcome of renal revascularization. Further work is
eeded to examine the third and fourth items, specifically
iagnostic tools to establish the role of vascular occlu-
ive lesions in generating disease and the likelihood of
linical benefit after restoration of vessel patency. Further
tudies in the renal vasculature should be aimed at
efining these characteristics more fully. Clinicians remain
n sore need of better tools to identify renal parenchyma at
rue risk of “ischemic injury” and to identify when kidney
unction can be (or can no longer be) improved with renal
evascularization.
eprint requests and correspondence: Dr. Stephen C. Textor,
ayo Clinic, Nephrology and Hypertension, W19, 200 First
treet, SW, Rochester, Minnesota 55905. E-mail: textor.
tephen@mayo.edu.
Table 2. Issues Central to Determining Role for Renal Revascularization
in Atherosclerotic RAS
Questions Tools for Evaluation
1. Severity of vascular
occlusion?
Quantitative angiography, translesional gradients,
intravascular ultrasound, Doppler
2. Treatable? Vessel location, associated disease, accessory
vessels, aneurysm, occlusion
3. Responsible for disease? Evident activation of pressor systems, for example,
renin
Duration of change, such as blood pressure, renal
function, other measures of tissue ischemia
(e.g., BOLD MRI, PET energy consumption),
activation of ﬁbrogenic, inﬂammatory, or
oxidative pathways
4. Beneﬁt from
revascularization?
Rapidity of evolution, pre-existing injury (e.g.,
hypertension, diabetes, other kidney disease),
comorbid disease risk, associated procedural
risk to kidney (e.g., atheroembolic potential),
response to other medical therapy
Risk of disease progression, salvagability of kidney
function (resistive index, BOLD MRI)
BOLD MRI  blood oxygen level–dependent magnetic resonance imaging; PET  positron
emission tomography; RAS renal artery stenosis.EFERENCES
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